While it is difficult to make recommendations about specific chemotherapy regimens since neoadjuvant regimens (and subsequent adjuvant treatment) differed across trials (see Table 2), the totality of the evidence supports the REAL recommendation that neoadjuvant chemotherapy + HP is the standard of care for patients with HER2+ early breast cancer with tumours ≥cT2 or those with node-positive disease (cN+). The gene discussed is ERBB2; the disease is breast cancer.